/
Oncology
Advanced Hepatocellular Carcinoma
10
Pipeline Programs↗
5
Active Trials↗
5
Companies Involved↗
Advanced Hepatocellular Carcinoma is an early-stage landscape with 10 programs across 5 companies. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical4
Phase 1
No programs
Phase 2
No programs
Phase 36
Approved
No programs
Analysis
Modality Breakdown
67%
Monoclonal antibody
6 of 9 classified programs — the dominant modality here.
Monoclonal antibody leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 90% of 10 pipeline programs.
Analysis
Trial Status
9
clinical trials
Recruiting4 · 44%
Completed3 · 33%
Suspended1 · 11%
Active, not recruiting1 · 11%
Clinical Trials
Trial Activity
9 trials
Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study
Completed·—·Phase 2·NCT05117957·50 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)